Antitumor activity of the novel human cytokine AIMP1 in an in vivo tumor model

Yeon Sook Lee, Jung Min Han, Taehee Kang, Young In Park, Hwan Mook Kim, Sunghoon Kim

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Although AIMP1 (previously known as p43) is one of three auxiliary proteins bound to a macromolecular aminoacyl tRNA complex, it is also secreted as a cytokine controlling both angiogenesis and immune responses. Here we show that systemically administered purified recombinant human AIMP1 had anti-tumor activity in mouse xenograft models. In Meth A-bearing Balb/c mice, tumor volume increased about 28 fold in the vehicle treatment group, while an increase of about 16.7 fold was observed in the AIMP1-treated group. We also evaluated the anti-tumor activity of AIMP1 in combination with a sub-clinical dose of the cytotoxic anti-tumor drug, paclitaxel. The growth of NUGC-3 human stomach cancer cells was suppressed by 84% and 94% by the combinations of 5 mg/kg paclitaxel + 25 mg/kg AIMP1 (p = 0.03), and 5 mg/kg paclitaxel + 50 mg/kg AIMP1 (p = 0.02), respectively, while 5 mg/kg paclitaxel alone suppressed growth by only 54% (p = 0.02). A similar cooperative effect of AIMP1 and paclitaxel was observed in a lung cancer xenograft model. These results suggest that AIMP1 may be useful as a novel anti-tumor agent.

Original languageEnglish
Pages (from-to)213-217
Number of pages5
JournalMolecules and cells
Volume21
Issue number2
Publication statusPublished - 2006 Apr 30

    Fingerprint

All Science Journal Classification (ASJC) codes

  • Molecular Biology
  • Cell Biology

Cite this